Medopa (CARDIAC THERAPY)

Medopa (CARDIAC THERAPY) Uses, Dosage, Side Effects, Food Interaction and all others data.

Medopa (CARDIAC THERAPY) Hydrochloride Injection is a clear and colorless solution for intravenous infusion after dilution.

Medopa (CARDIAC THERAPY) hydrochloride can stimulate alpha, beta and dopamine receptors. At infusion rates of 0.5 to 2 micrograms/kg/min, dopamine receptors are selectively activated and blood pressure either does not change or decrease slightly. The most important effects are renal and mesenteric vasodilatation. Renal plasma flow, glomerular filtration rate and sodium excretion usually increase. At infusion rates of 2 to 10 micrograms/kg/min, beta1-receptors are activated and cardiac output and systolic blood pressure increase.

Medopa (CARDIAC THERAPY) stimulates dopaminergic receptors at lower doses producing renal and mesenteric vasodilation; at higher doses stimulates both dopaminergic and β1-adrenergic receptors producing cardiac stimulation and renal vasodilation; large doses stimulates α-adrenergic receptors.

Medopa (CARDIAC THERAPY) is a natural catecholamine formed by the decarboxylation of 3,4-dihydroxyphenylalanine (DOPA). It is a precursor to norepinephrine in noradrenergic nerves and is also a neurotransmitter in certain areas of the central nervous system, especially in the nigrostriatal tract, and in a few peripheral sympathetic nerves. Medopa (CARDIAC THERAPY) produces positive chronotropic and inotropic effects on the myocardium, resulting in increased heart rate and cardiac contractility. This is accomplished directly by exerting an agonist action on beta-adrenoceptors and indirectly by causing release of norepinephrine from storage sites in sympathetic nerve endings.

Trade Name Medopa (CARDIAC THERAPY)
Availability Prescription only
Generic Dopamine
Dopamine Other Names 3-Hydroxytyramine, Dopamina, Dopamine, Dopaminum, Oxytyramine
Related Drugs furosemide, dexamethasone, Lasix, methylprednisolone, hydrocortisone, torsemide, epinephrine, Medrol, Decadron, Demadex
Type
Formula C8H11NO2
Weight Average: 153.1784
Monoisotopic: 153.078978601
Protein binding

No information currently available on protein binding.

Groups Approved
Therapeutic Class Inotropic-sympathomimetics
Manufacturer
Available Country Malta, Portugal
Last Updated: September 19, 2023 at 7:00 am
Medopa (CARDIAC THERAPY)
Medopa (CARDIAC THERAPY)

Uses

Medopa (CARDIAC THERAPY) is recommended for the correction of haemodynamic imbalance present in-

  • Acute hypotension or shock associated with myocardial infarction, endotoxic septicaemia, trauma and renal failure.
  • As an adjunct after open heart surgery, where there is persistent hypotension after correction of hypovolaemia.
  • In chronic cardiac decompensation as in congestive failure.

Medopa (CARDIAC THERAPY) is also used to associated treatment for these conditions: Arrhythmia, Circulatory collapse and shock, Hypotension caused by Trauma, endotoxic septicemia, Open-heart Surgery, Renal Failure, chronic cardiac decompensation, Myocardial Infarction, Urine flow decreased caused by Trauma, endotoxic septicemia, Open-heart Surgery, Renal Failure, chronic cardiac decompensation, Myocardial Infarction, Decreased cardiac output caused by Trauma, endotoxic septicemia, Open-heart Surgery, Renal Failure, chronic cardiac decompensation, Myocardial Infarction

How Medopa (CARDIAC THERAPY) works

Medopa (CARDIAC THERAPY) is a precursor to norepinephrine in noradrenergic nerves and is also a neurotransmitter in certain areas of the central nervous system. Medopa (CARDIAC THERAPY) produces positive chronotropic and inotropic effects on the myocardium, resulting in increased heart rate and cardiac contractility. This is accomplished directly by exerting an agonist action on beta-adrenoceptors and indirectly by causing release of norepinephrine from storage sites in sympathetic nerve endings. In the brain, dopamine actas as an agonist to the five dopamine receptor subtypes (D!, D2, D3, D4, D5).

Dosage

Medopa (CARDIAC THERAPY) dosage

Intravenous-Acute heart failure:

  • Adult: Initially, 2-5 mcg/kg/min, increased gradually by up to 5-10 mcg/kg/min according to patient’s cardiac and urine output. Seriously ill patient: Up to 20-50 mcg/kg/min may be required.

Dilute solution (usually 1.6 mg/ml or 3.2 mg/ml) in glucose 5%, NaCl 0.9% or other suitable diluent. More dilute solution may be used where fluid expansion is not a problem.

Side Effects

Ectopic heartbeats, angina, tachycardia, palpitation, hypotension, vasoconstriction, dyspnoea, nausea, vomiting, headache, cardiac conduction abnormalities, HTN, azotemia, anxiety, widened QRS complex, bradycardia, piloerection, peripheral cyanosis.

Toxicity

LD50 oral mice = 1460 mg/kg, LD50 oral rats = 1780 mg/kg. Spasm or closing of eyelids, nausea, vomiting, cardiac arrhythmias, involuntary movements of the body including the face, tongue, arms, hand, head, and upper body; hypotension, haemolytic anaemia, urinary retention, duodenal ulcer, sialorrhea, ataxia, abdominal pain, dry mouth, nightmares, tachypnoea, bruxism, confusion, and insomnia.

Precaution

Patient with CV disease, cardiac arrhythmias and/or occlusive vascular disease, active myocardial ischaemia or recent MI. Correct hypovolaemia prior to treatment. Pregnancy and lactation.

Interaction

Cyclopropane and halogenated hydrocarbon anaesth may enhance the arrhythmogenic effect of dopamine. Cardiac effects are antagonised by β-adrenergic agents (e.g. propanolol, metoprolol). α-adrenergic blocking agents may antagonise the vasoconstricting effect of high dose dopamine. Prolonged and enhanced effect with MAOIs. Risk of hypotension and bradycardia with phenytoin. May potentiate diuretic effect of hydrochlorothiazide or furosemide. Enhanced vasopressor effect with TCAs and guanethidine. Risk of excessive vasoconstriction with ergot alkaloids.

Food Interaction

No interactions found.

Elimination Route

Medopa (CARDIAC THERAPY) is rapidly absorbed from the small intestine.

Half Life

2 minutes

Elimination Route

It has been reported that about 80% of the drug is excreted in the urine within 24 hours, primarily as HVA and its sulfate and glucuronide conjugates and as 3,4-dihydroxyphenylacetic acid. A very small portion is excreted unchanged.

Pregnancy & Breastfeeding use

Pregnancy: It is not known whether dopamine crosses the placental barrier. The benefits of using this product should be weighed against the possible risks to the fetus.

Lactation: It is not recommended for breast-feeding mothers unless the expected benefits outweigh any potential risks.

Contraindication

Administration of dopamine is contraindicated in the following cases: Pheochromocytoma, atrial or ventricular tachyarrhythmias, ventricular fibrillation, hyperthyroidism, concurrent use with ergotamine.

Acute Overdose

Symptoms: Excessive BP elevation, vasoconstriction.

Management: Reduce dose or discontinue infusion. May also consider infusion of phentolamine mesylate.

Storage Condition

Store below 30 °C and protect from light.

Innovators Monograph

You find simplified version here Medopa (CARDIAC THERAPY)

Medopa (CARDIAC THERAPY) contains Dopamine see full prescribing information from innovator Medopa (CARDIAC THERAPY) Monograph, Medopa (CARDIAC THERAPY) MSDS, Medopa (CARDIAC THERAPY) FDA label

http://classyfire.wishartlab.com/tax_nodes/C0000000
http://classyfire.wishartlab.com/tax_nodes/C0002448
http://classyfire.wishartlab.com/tax_nodes/C0000134
http://classyfire.wishartlab.com/tax_nodes/C0001286
http://classyfire.wishartlab.com/tax_nodes/C0000182
http://classyfire.wishartlab.com/tax_nodes/C0000186
http://classyfire.wishartlab.com/tax_nodes/C0004253
http://classyfire.wishartlab.com/tax_nodes/C0003899
http://classyfire.wishartlab.com/tax_nodes/C0004647
http://classyfire.wishartlab.com/tax_nodes/C0004646
http://classyfire.wishartlab.com/tax_nodes/C0004557
http://classyfire.wishartlab.com/tax_nodes/C0000323
http://classyfire.wishartlab.com/tax_nodes/C0000469
http://classyfire.wishartlab.com/tax_nodes/C0004150
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:18243
http://www.genome.jp/dbget-bin/www_bget?cpd:C03758
http://www.hmdb.ca/metabolites/HMDB0000073
http://www.genome.jp/dbget-bin/www_bget?drug:D07870
http://www.genome.jp/dbget-bin/www_bget?cpd:C03758
https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=681
https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46506043
https://www.chemspider.com/Chemical-Structure.661.html
http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=55121
https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=3628
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=18243
https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL59
https://zinc.docking.org/substances/ZINC000000033882
http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000212
http://www.pharmgkb.org/drug/PA449396
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940
https://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/LDP
http://www.rxlist.com/cgi/generic3/dopamine.htm
https://www.drugs.com/cdi/dopamine.html
https://en.wikipedia.org/wiki/Dopamine
*** Taking medicines without doctor's advice can cause long-term problems.
Share